Aptus Pharma IPO Is Gearing Up To Hit the Dalal Street!

The Indian pharmaceutical sector is third in terms of output volume, with expectations to reach USD 130 billion by 2030 and USD 450 billion by 2047. Moreover, Indian maintains a dominating position in global pharmaceuticals, by contributing 20% of the global generic drug exports. Amidst these trends, Aptus Pharma IPO is entering the Indian equity space.

Bigshare Services Private Limited is registering the Aptus Pharma IPO, while Interactive Financial Services Limited is managing it. Check the status of the allotment.

For more information regarding the Aptus Pharma IPO price, date, size, etc., check out the Aptus Pharma DRHP and RHP.

Note: 50% shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.

Aptus Pharma: Company Profile

Particulars	Descriptions
Began	2011
Business	Marketing and distribution of pharmaceutical formulations
Manufacturing	Contract manufacturing model with 7 units
Self-owned manufacturing	None
Categories	Gastrointestinal, anti-allergic, anti-infectives, neuro-psychiatric, general wellness products, nutritional supplements, pain management, etc.
Form Categories	Tablets, syrups, capsules, injections, creams, lotions, gels, drops, etc.
Promoters	Tejash Maheshchandra Hathi, Riddhish Natwarlal Tanna, Ghanshyam Vinubhai Pansuriya, etc.
Product divisions	Products are categorised into 4 categories: Aptus CD Care (Cardiac Diabetic Division), Aptus Global (Export Division), Aptus Pharma (Pioneer Division) and Aptus Wellcare (Wellcare Division)
SKUs	194
Domestic Presence	Gujarat (largest market) and West Bengal
Peers	Lincoln Pharmaceuticals Limited, Zota Health Care Limited and Sunrest Lifescience Limited

The Ultimate Aptus Pharma IPO Review

From Aptus Pharma share price, size, date, etc., to GMP and financials, explore all key takeaways from this IPO to make an informed decision.

Aptus Pharma IPO Date

Events	Date
Opening	23 September 2025
Closing	25 September 2025
UPI Mandate End	25 September 2025 (5 PM)
Allotment	26 September 2025
Refund	29 September 2025
Shares moving to demats	29 September 2025
Listing	30 September 2025

Aptus Pharma IPO Price and Size

Particulars	Shares	Aggregate Value (₹ Cr)
Fresh Issue	18,60,000	13.02
Offer for Sale	NIL	NIL
Overall Issue	18,60,000	13.02

Aptus Pharma IPO Objectives

Particulars	Amount (₹ Lakhs)
Office Premise	162.95
Working Capital	800.00
Other corporate requirements	Undisclosed

Other Takeaways from Aptus Pharma IPO

Particulars	Description
Face value of each share (₹)	10
Price Range (₹)	65 to 70
Lot size (shares)	2,000
Listed At	BSE SME

Aptus Pharma IPO: Investors Categorisation

Investor	Allotment
QIB	Maximum 50% of the Issue
NIB	Minimum 15% of the Issue
RIB	Minimum 35% of the Issue

Anchor Investor Details in Aptus Pharma IPO Review

Particulars	Description
Opening Date	22 September 2025
Terms of Payment	Full payment is required upon submission of a bid

Don’t miss out on these limited deals on top demat accounts!

Key Financials of Aptus Pharma

Particulars	2025	2024	2023
Revenue from Operations (₹ Lakhs)	2,455.77	1,785.70	1,389.73
Total Income (₹ Lakhs)	2,463.64	1,788.23	1,389.73
EBITDA (₹ Lakhs)	475.70	149.30	57.46
EBITDA Margin (%)	19.31	8.35	4.13
PAT (₹ Lakhs)	309.96	79.81	19.43
Net Profit Ratio (%)	12.62	4.47	1.40
Current Ratio	1.63	2.01	1.81
Debt Equity Ratio	1.49	3.00	2.28
ROE (%)	44.50	45.18	20.06
ROCE (%)	45.66	21.70	12.77

Aptus Pharma IPO: Strengths and Risks

The main benefits and concerns of the IPO are covered here.

Strengths

Portfolio: With over 194 pharmaceutical formulations, the firm offers a wide variety of products.
Distribution Network: The business has a robust and widespread distribution network that helps boost financials.
Manufacturing: The company has seven strategically located contract manufacturing deals with production plants.
High Quality: The company strives to maintain optimal product quality with quality certifications to ensure customer satisfaction.

Risk

Manufacturing: The company does not have its own manufacturing facilities, limiting its control and creating concerns.
Compliance: Being in the pharmaceutical industry, the company has to renew permits and adhere to other regulatory requirements.
Revenue Concentration: The top ten customers of the company contribute 48.84% of the total revenue.
Intellectual Property: Inability to protect the intellectual properties belonging to the company might impact business operations.

Apply or Avoid the Aptus Pharma IPO

The Aptus Pharma IPO GMP is unavailable, currently. However, the GMP might change soon. Stay updated with the latest GMP. Don’t forget to check the detailed analysis, along with their RHP and DRHP, to understand the Aptus Pharma IPO size, date, financials, etc.

Stay tuned with the live subscription status before hitting APPLY.

FAQs

What is the Aptus Pharma IPO date?

The Aptus Pharma IPO opens on 23 September 2025 and ends on 25 September 2025. Check out the live subscription data in real time.

What is the Aptus Pharma IPO price?

The company has aimed for an overall issue of ₹ 13.02 Crore. The particular IPO size and price range are currently unavailable. Also, don't forget to check the Aptus Pharma IPO live subscription status before applying.